New radiation therapy shows promise for slowing prostate cancer spread
NCT ID NCT04443062
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a drug called Lutetium-177-PSMA-617, which delivers radiation directly to prostate cancer cells. It included 58 men with prostate cancer that had spread to a few spots in bones or lymph nodes but was still hormone-sensitive. The study compared the drug to standard care to see if it could delay disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lutetium-177-PSMA-617 (a targeted radioactive drug)
What this could lead to
If successful, this could offer a new treatment option for men with prostate cancer that has spread to a few places, potentially delaying the need for stronger hormone therapy.
What could go wrong
This is a small, early-phase study with only 58 participants. The treatment may not work better than standard care, and there are risks from radiation exposure to healthy tissues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amsterdam UMC
Amsterdam, Netherlands
-
German Oncology Center
Limassol, Cyprus
-
Radboud University
Nijmegen, Netherlands
-
University Medical Center Groningen
Groningen, Netherlands